

01 Jun 2021 | News

# Catchup Capsule: Key APAC Insights You Need To Read

by Ian Haydock

Given its ever-growing role as a critical component of the global biopharma industry, you can't afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.

A selection of key stories from the Asia-based content team for *Scrip* and the *Pink Sheet* over the past few weeks that you may have missed, reflecting the diversity and depth of issues facing the biopharma industry in this critical and fast-changing region.

In this edition: new industry incentives in Shanghai; research firms fret over Japan policy direction; investors flock to Korean biotech; experts share views on the impact of the US-proposed IP waiver for coronavirus vaccines; and *Scrip* takes an infographic look at the COVID-19 vaccine environment in India.

(Highlighted text provides links to the original story.)

## Cash, Lights, Go: Shanghai Takes On Boston In Latest Biopharma Policy Appeal

Developers of antibodies, novel vaccines and cell and gene therapies are all [\*slated to get funding support\*](#) as Shanghai unleashes a flurry of incentives and policies to lead China's push to become a global biopharma powerhouse.

## Research Industry Presents United Front On Japan Reforms

Three groups representing the domestic and multinational research-based pharma industry in Japan [\*present a unified position\*](#) as they call for policy changes they see as providing the right environment for investment, innovation and a sustainable healthcare system.

## Large-Scale Funding Rises In Korea Amid Biotech Investment Boom

After record venture capital activity around South Korean biotechs last year, the [\*strong investment interest has persisted\*](#) so far this year, with an increased number of companies receiving

large-scale funding as the promising sector emerges amid the pandemic.

### **Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?**

IP experts [\*share views on a range of critical issues\*](#) around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can't be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

### **Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge**

From mRNA to subunit vaccines, Indian companies have [\*20 COVID-19 vaccine candidates\*](#), while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume. (This article has been made free access with registration.)

Author Vibha Ravi talks about the main findings of her infographic and how she pulled the data together in the short video below. (Also available on YouTube [\*here\*](#).)

To receive notifications of all new Asia Pacific content, be sure to set your personalized alerts to include this topic (home page menu>regional coverage>Asia Pacific>set alert).

[\*Click here to explore this interactive content online\*](#) ✨